Covid-19 testing hub

Covid-19 diagnostics market analysis and updates

Covid-19 testing has become a key tool for countries around the world to develop containment and mitigation strategies to control the spread of SARS-CoV-2, a previously unknown coronavirus that emerged in Wuhan, China in December 2019.

The outbreak was characterised as a pandemic by the World Health Organization in March 2020. Now, more countries are shifting their covid-19 approach from pandemic to endemic.

The subsequent changes in government policy and the requirements for covid-19 surveillance and screening programmes will impact both test volume and the types of test technologies that will be frequently used.

Clearstate offers market data, forecasts and trend predictions to give you the insight on the progression and likely impact of covid-19 on the healthcare and IVD sector, enabling you to effectively plan ahead. Our covid-19 testing hub is regularly updated to share our findings on this new diagnostic market segment.

Inquire now

What is covid-19 testing?

Covid-19 diagnostics test for SARS-CoV-2 virus infection. There are various covid-19 test methods such as molecular-based tests performed at a laboratory, rapid antigen tests using point-of-care devices and antibody tests. Molecular assays, particularly those involving reverse transcription polymerase chain reactions (RT-PCR) are widely regarded as the gold standard in the confirmation of covid-19 infection.

Explore the latest covid-19 testing market insights

From market news to analysis, our articles provide concise and up-to-date information about the developments driving the covid-19 diagnostics market. Explore the latest in covid-19 diagnostics testing technology and how they are deployed in different settings. Uncover the challenges and opportunities countries face in disease screening and management through covid-19 testing. Understand the implications of covid-19 related testing needs and infrastructure investments on other test areas and their impact on the covid-19 testing market size.

Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels

Asia-Pacific (APAC) IVD markets have grown and exceeded their pre-pandemic size in 2019. This growth is largely due to covid-19 testing.

Rapid antigen tests to erode PCR-based molecular covid-19 test market in Asia-Pacific

Emergent covid-19 screening technologies coupled with declining testing demand are likely to erode the molecular-based covid-19 test market in Asia-Pacific (APAC) over the next five years.

Molecular diagnostics instrument sales in Asia-Pacific set to normalise as vaccination rates rise

Molecular diagnostics (MDX) instrument sales in Asia-Pacific (APAC) are expected to normalise in the next few years due to the high installed base, a result of government-mandated instrument purchases. These purchases caused a significant influx of new molecular analyser installations during the initial pandemic-hit years.

Covid-19: Three purchasing behaviour trends at molecular labs (Asia-Pacific)

Covid-19 has not only impacted test volumes but also spurred changes in test practices and purchasing behaviour in Asia-Pacific’s (APAC’s) molecular diagnostics (MDx) labs.

[On-demand Webinar] Covid-19 Impact: Molecular Diagnostic (MDx) Market

Clearstate zooms in on two of the fastest-growing molecular testing areas: cancer and covid-19 testing to uncover the market opportunities for IVD companies.

[On-demand webinar] will covid-19 accelerate the next wave of adoption of next-generation sequencing (NGS) in healthcare?

Sequencing-based diagnostic testing has been on the uptrend, with the adoption of next-generation sequencing (NGS) testing in oncology, genetics and prenatal screening – areas where the vast majority is done – continuing to grow strongly.

Understand the covid-19 diagnostics and testing market

With high unpredictability in covid-19 test demand, we provide an understanding of trends for caseloads, government response and policy changes to disease management, covid-19 test capacity and testing technology, to enable you to effectively plan ahead to meet test demand.

Our reports show how and where businesses can capture opportunities as covid-19 continues to impact markets.

report by clearstate

The future of molecular diagnostics following the covid-19 crisis in Asia-Pacific

This report examines how the covid-19 pandemic has shifted the dynamics of molecular testing in APAC, as well as the future of the region’s MDx market. As molecular testing capabilities advance, will covid-19 related investments benefit other test areas?

Learn more

Infectious diseases article by Clearstate

report by clearstate

Keeping ahead of infectious diseases in Asia-Pacific with increased testing

Our reports show how and where businesses can capture opportunities as laboratories adopt MDx across a wide range of applications.

Learn more

Report by clearstate

Asia-Pacific’s IVD market: post-pandemic recovery trends and the future outlook

This paper examines the Asia-Pacific (APAC) region where the virus first emerged, across the timeline from 2019 to 2021 in 16 markets, to find out if the IVD market has fully rebounded from the disruption of covid-19.

Learn more

Clearstate newsletter

Sign up to our newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts.